¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"long acting insulin"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • long-arm cast
    ±äÆÈ¼®°íºØ´ë
  • long-leg cast
    ±ä´Ù¸®¼®°íºØ´ë
  • long-term care
    Àå±â¿ä¾ç¼­ºñ½º
  • long-term illness
    Àå±âÁúȯ
  • long-term potentiation
    Àå±â°­È­ÀÛ¿ë
  • parasternal long axis view
    º¹Àå»ÀÁÖÀ§±äÃà´Ü¸éµµ
  • crystalline insulin
    °áÁ¤Àν¶¸°
  • depot insulin
    ÀúÀåÀν¶¸°
  • immunoreactive insulin
    ¸é¿ª¹ÝÀÀÀν¶¸°
  • insulin
    Àν¶¸°
  • insulin clamp
    Àν¶¸°Å¬·¥ÇÁ
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • insulin resistance
    Àν¶¸°ÀúÇ×, Àν¶¸°³»¼º
  • insulin sensitivity index
    Àν¶¸°¹Î°¨Áö¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • long-term potentiation
    ÀÚ±â»ó½ÂÀÛ¿ë
  • parasternal long axis view
    Èä°ñ¿¬ÀåÃà´Ü¸éµµ
  • crystalline insulin
    °áÁ¤Àν¶¸°
  • depot insulin
    ÀúÀåÀν¶¸°
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • glucose insulin tolerance test
    Æ÷µµ´çÀν¶¸°°ßµõ°Ë»ç
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • insulin
    Àν¶¸°
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • immunoreactive insulin
    ¸é¿ª¹ÝÀÀÀν¶¸°
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin resistance
    Àν¶¸°ÀúÇ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Insulin shock
    Àν¶¸°¼ï
  • Insulin-like growth factors
    Àν¶¸°¾ç(å×)¼ºÀå(à÷íþ)È£¸£¸ó
  • anti-insulin
    Ç×Àν¶¸°.
  • arginine-insulin test
    ¾Æ¸£±â´Ñ-Àν¶¸°½ÃÇè
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • high purified insulin
    °í¼ø¼öÀν¶¸°.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • insulin secreting islet cell tumor
    Àν¶¸° ºÐºñ¼º µµ¼¼Æ÷Á¾¾ç.
  • insulin sensitivity
    Àν¶¸°°¨(¼ö)¼º.
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö.
  • insulin sensitivity test
    Àν¶¸°°¨¼º½ÃÇè.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • crystalline insulin
    °áÁ¤¼º Àν¶¸°.
  • crystalline zinc insulin
    °áÁ¤¼º ¾Æ¿¬(Ì¿ïÜàõ䬿ç)Àν¶¸°.
  • depot insulin
    ÀúÀåÀν¶¸°.
  • diabetes mellitus,insulin deficiency
    Àν¶¸° °áÇÌÁõ(¡­ÌÀù¹ñø)
  • diabetes mellitus,insulin resistance
    Àν¶¸° ÀúÇ×(¼º)(¡­î½ù÷àõ)
  • diabetes mellitus,insulin-dependent
    Àν¶¸° ÀÇÁ¸¼º(¡­ëîðíàõ)
  • diabetes mellitus,non-insulin-dependent
    ºñ-Àν¶¸° ÀÇÁ¸¼º(Þª¡­)
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • high purified insulin
    °í¼ø¼öÀν¶¸°.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin
  • insulin antagonist
    Àν¶¸°±æÇ×ü.
  • insulin antagonist
    Àν¶¸°±æÇ×Á¦.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • very long-chain fatty acids
    ¸Å¿ì ±ä »ç½½ Áö¹æ»ê(ò·Û¸ß«)
  • anti-insulin
    Ç×(ù÷)Àν¶¸°
  • atypical insulin
    ºñÁ¤Çü (ÞªïÒúþ)Àν¶¸°
  • bound insulin
    °áÇÕ(Ì¿ùê)Àν¶¸°
  • desalanine insulin
    ¾Ë¶ó´ÑÁ¦°Å(ð¶ËÛ)Àν¶¸°
  • free insulin
    À¯¸®(ë´×î) Àν¶¸°
  • globin zinc insulin
    ±Û·Îºó ¾Æ¿¬(䬿ç)Àν¶¸°
  • immunoreactive insulin
    ¸é¿ª¹ÝÀÀ¼º(Øóæ¹Úãëëàõ) Àν¶¸°
  • insulin
    Àν¶¸°
  • insulin resistance index
    Àν¶¸° ÀúÇ×Áö¼ö(î½ù÷ò¦â¦)
  • insulin shock
    Àν¶¸° ¼ï
  • insulin stimulating test
    Àν¶¸° ÀڱؽÃÇè(í©Ð½ãËúÐ)
  • insulin tolerance test
    Àν¶¸° ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • isophane insulin
    ¾ÆÀÌ¼ÒÆÇ Àν¶¸°
  • lente insulin
    ·»Å×Àν¶¸°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LATS-P long-acting thyroid stimulator-protector
SAARD slow-acting antirheumatic drug
NPH   1) Neutral Protamine Hagedorn Insulin
    = Isophane Insulin Susp...
AITT arginine insulin tolerance test; augmented insulin tolerance test
IRI immunoreactive insulin; insulin resistance index
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LTR 1-long terminal repeat
hLTBMC human long-term bone marrow culture
L Long
LCP Long Chain Polyunsaturated fatty acids
LD Long Days
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • zinc insulin crystals
    ¾Æ¿¬ Àν¶¸° °áÁ¤
  • long
    ±ä
  • long bone
    ±ä »À, Àå°ñ
    »çÁö¿¡¼­ º¸´Â »À·Î¼­ ´ëÅð°ñ, ºñ°ñ, °æ°ñ µîÀÌ ÀÖ´Ù.
  • long buccal nerve
    ÀåÇù ½Å°æ
  • long cure
    Àú¿Â Àå½Ã°£ ¿Â¼º¹ý
    160'F ¹°¿¡¼­ 8¡­9½Ã°£ µ¿¾È ¹æÄ¡ÇÏ´Â ¿Â¼º¹ýÀÌ´Ù. ÃßõÇÒ¸¸ÇÑ ¹æ¹ýÀÌ´Ù.
  • long dental appointment
    Àå½Ã°£ÀÇ Ä¡°ú Ä¡·á
  • long distance irradiation
    ¿ø°Ý Á¶»ç, ¿ø°Ý Á¶»ç¹ý
  • long history
    ¿À·¡µÈ º´·Â
  • long pin porcelain facing
    Àåħ ÀüÀå µµÄ¡
  • long sight
    ¿ø½Ã
    µ¿ÀǾî=hy
  • long term illness
    Àå±â Áúȯ
  • long tract syndrome
    Àå°æ·Î ÁõÈıº
  • long-standing
    Àå±âÀÇ
  • long-term exposure
    Àå±â ³ëÃâ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
globin insulin A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours.
Synonym: globin insulin.
(05 Mar 2000)
globin zinc insulin A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours.
Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes.
Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin.
Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus.
Synonym: NPH insulin.
(05 Mar 2000)
crystalline insulin zinc suspension A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours.
Synonym: crystalline insulin zinc suspension.
(05 Mar 2000)
prompt insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
protamine zinc insulin Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml.
(05 Mar 2000)
semilente insulin Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
non-insulin-dependent diabetes mellitus <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop.
(05 Mar 2000)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
NPH insulin isophane insulin
diabetes mellitus, insulin-dependent Diabetes mellitus characterised by insulin deficiency, sudden onset, severe hyperglycaemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
(12 Dec 1998)
diabetes mellitus, non-insulin-dependent Diabetes characterised by the ability to survive without ketoacidosis in the absence of insulin therapy. It is usually of slow onset and patients exhibit a tendency to obesity.
(12 Dec 1998)
insulin <drug, growth factor, hormone> A polypeptide hormone (bovine insulin, 5780D) found in both vertebrates and invertebrates.
Secreted by the _ cells of the pancreas in response to high blood sugar levels, it induces hypoglycaemia. Defective secretion of insulin is the cause of diabetes mellitus. Insulin is also a mitogen, has sequence homologies with other growth factors and is a frequent addition to cell culture media for demanding cell types.
(18 Nov 1997)
insulin activating factor <chemical> Activates insulin gene transcription in pancreatic beta cells.
Synonym: insaf
(05 Dec 1998)
insulin allergy When a person's body has an allergic or bad reaction to taking insulin made from pork or beef or from bacteria, or because the insulin is not exactly the same as human insulin or because it has impurities. The allergy can be of two forms. Sometimes an area of skin becomes red and itchy around the place where the insulin is injected. This is called a local allergy. In another form, a person's whole body can have a bad reaction. This is called a systemic allergy. The person can have hives or red patches all over the body or may feel changes in the heart rate and in the rate of breathing. A doctor may treat this allergy by prescribing purified insulins or by desensitisation.
See: desensitisation.
(09 Oct 1997)
insulin antagonist Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • E.long.
    east longitude
  • Long Beach
    ¹Ì±¹ Los Angeles ±Ù±³ÀÇ µµ½Ã;ÇØ¼ö¿åÀå
  • Long Island
    ·Õ ¼¶(¹Ì±¹ New YorkÁÖ ³²µµºÎÀÇ ¼¶)
  • Long Island Slund
    ·Õ ¾Æ¸±·£µå »ç¿îµå
  • Long John
    Ű´Ù¸®
  • Long March
    (the~)(Áß±¹ °ø»ê´çÀÇ)´ë ÀåÁ¤
  • Long Tom
    Àå°Å¸®Æ÷
  • long
    ±ä;±æ´Ù¶õ;¿À·¡ °É¸®´Â;Áö·çÇÑ;ÀåÀ½ÀÇ;°­¼¼ÀÇ;´Ù·®ÀÇ;a ~ way off ¸Õ (from);draw a ~ face ħ¿ï(Â·è)ÇÑ ¾ó±¼À» ÇÏ´Ù
  • long
    ±æ°Ô;¿À·§µ¿¾È;ÀüºÎÅÍ;...ÁÙ°ð;all day ~ Á¾ÀÏ;any ~er ¹ú½á;ÀÌ ÀÌ»ó;at (the) ~est ±æ¾î¾ß;±â²¯Çؾß;no ~er ÀÌ¹Ì ... ¾Æ´Ï´Ù;...À̸é
  • long
    ¿À·§µ¿¾È;Çϱâ ÈÞ°¡;Àå¸ðÀ½;before(ere)~ ¸ÓÁö ¾Ê¾Æ;for ~ ¿À·§µ¿¾È;The ~ and the short of it is that ... °£´ÜÈ÷ ¸»ÇÏÀÚ¸é;°á±¹Àº
  • long
    °£ÀýÈ÷ ¹Ù¶ó´Ù;»ç¸ðÇÏ´Ù
  • long clothes
    ¹è³»¿Ê;±âÀú±Í
  • long date
    Àå±âÀÇ »óȯ ±âÀÏ
  • long distance
    Àå°Å¸® ÀüÈ­;Àå°Å¸® ±³È¯±¹(¼ö)
  • long division
    ÀåÁ¦¹ý(12)ÀÌ»óÀÇ ¼ö·Î ³ª´©´Â ³ª´°¼À
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á